TRB Advisors’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

TRB Advisors’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,000	Closed	-$274K	–	10
2022 Q4	$274K	Hold	19,000	–	–	0.27%	4
2022 Q3	$952K	Hold	19,000	–	–	0.94%	4
2022 Q2	$1.62M	Hold	19,000	–	–	1.01%	5
2022 Q1	$2.87M	Hold	19,000	–	–	1.57%	6
2021 Q4	$5.68M	Hold	19,000	–	–	1.83%	8
2021 Q3	$7.41M	Buy	19,000 +667	+4%	+$284K	2.68%	8
2021 Q2	$7.74M	Hold	18,333	–	–	1.75%	10
2021 Q1	$8.75M	Buy	+18,333	New	+$9.34M	3.36%	8

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

TRB Advisors's FNCH Position: Q1 2023 in Review

TRB Advisors sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2023, closing a stake of 19,000 shares — an estimated $274K sold.

TRB Advisors first reported a position in FNCH in Q1 2021 and held it in 8 quarters. The position peaked at $8.75M in Q1 2021. 33 funds tracked by Wall St. Rank hold FNCH as of Q1 2023.

TRB Advisors reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
TRB Advisors sold 19,000 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2023, an estimated $274K.
TRB Advisors first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
TRB Advisors's Finch Therapeutics Group, Inc. Common Stock position peaked at $8.75M in Q1 2021.
33 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2023.

Based on TRB Advisors's 13F filing for Q1 2023, filed 24 Apr 2023.